Quarterly report pursuant to Section 13 or 15(d)

Collaboration and License Agreements - Additional Information (Detail)

v3.3.0.814
Collaboration and License Agreements - Additional Information (Detail)
1 Months Ended 3 Months Ended 9 Months Ended
Jun. 30, 1998
USD ($)
Sep. 30, 2015
USD ($)
Sep. 30, 2014
USD ($)
Sep. 30, 2015
USD ($)
Agreement
Sep. 30, 2014
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
License agreement date       Jun. 30, 1998  
Monthly license fees $ 2,000        
Potential future development payments $ 800,000        
Development payment   $ 0 $ 0 $ 0 $ 0
Royalty payment   0 0 0 0
Janssen Pharmaceutical NV [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Payments made under agreement   0 0 0 0
Royalties received   0 $ 0 $ 0 $ 0
Janssen Pharmaceutical NV [Member] | Maximum [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Percentage of royalty on net sales       8.00%  
Janssen Pharmaceuticals, Inc. [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
License agreement date       Jun. 30, 2010  
Number of development and license agreements | Agreement       2  
Contingent payment eligible to receive on development and commercial events   $ 228,000,000   $ 228,000,000  
License termination date       2015-04